课题基金 / 基金详情

TRITIUM NMR ANALYSIS OF VT247: CARDIOVASCULAR & PULMONARY DISEASE

TRITIUM NMR ANALYSIS OF VT247: CARDIOVASCULAR & PULMONARY DISEASE
VT247 的氚核磁共振分析:心血管
批准号:
6220442
负责人:
PHILIP G. WILLIAMS
金额:
$0.52万
依托单位国家:
美国
项目类别:
财政年份:
1998
资助国家:
美国
项目状态:
已结题
起止时间:
1998-08-01 至 2000-07-31

项目摘要

项目成果

PHILIP G. WILLIAMS的其他基金

相似基金

相关文献

中文摘要
翻译
根据合同,受试化合物的氚标签为 作为一家小企业,Vitrax,Inc.缺乏资源来 对标记产品进行氚核磁共振分析。这样的核磁共振研究 用于确认氚标签的位置和级别,作为最终结果 为客户提供质量保证。VT247是一种新药 正在接受心血管和肺部疾病评估的候选人 申请。仅进行氚和质子核磁共振分析。用户详细信息: 实验详细信息:用户编号:1707核磁共振城市,州:Placania, CA 1 DAY资金来源:行业1复合收费:243.07美元计划 收入:243.06美元
英文摘要
The subject compound was tritium labelled under contract at Vitrax, Inc. As a small business, Vitrax, Inc. lacks the resources to conduct tritium NMR analyses of labelled products. Such NMR studies serve to confirm the site and level of tritium labelling, as a final step in the quality assurance for customers. VT247 is a new drug candidate under evaluation for cardiovascular and pulmonary disease applications. Tritium and proton NMR analyses only. User Details: Experiment Details: User Number: 1707 NMR City, State: Placentia, CA 1 day Funding Source: Industry 1 compound Charge: $243.07 Program Income: $243.06
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
THERMAL OXIDATION OF ORGANIC CHEMICALS USING CATALYTIC CHEMICAL OXIDATION
TRITIUM NMR ANALYSIS OF VT247: CARDIOVASCULAR & PULMONARY DISEASE
WORLD WIDE WEB SITE: DISSEMINATION & EDUCATION: TRITIUM LABELLING
TRITIUM NMR ANALYSIS VT279 & VT286: CARDIOVASCULAR & PULMONARY DISEASE: SODIUM
海外基金